Literature DB >> 12634013

Rational design and engineering of therapeutic proteins.

Shannon A Marshall1, Greg A Lazar, Arthur J Chirino, John R Desjarlais.   

Abstract

An increasing number of engineered protein therapeutics are currently being developed, tested in clinical trials and marketed for use. Many of these proteins arose out of hit-and-miss efforts to discover specific mutations, fusion partners or chemical modifications that confer desired properties. Through these efforts, several useful strategies have emerged for rational optimization of therapeutic candidates. The controlled manipulation of the physical, chemical and biological properties of proteins enabled by structure-based simulation is now being used to refine established rational engineering approaches and to advance new strategies. These methods provide clear, hypothesis-driven routes to solve problems that plague many proteins and to create novel mechanisms of action. We anticipate that rational protein engineering will shape the field of protein therapeutics dramatically by improving existing products and enabling the development of novel therapeutic agents.

Mesh:

Substances:

Year:  2003        PMID: 12634013     DOI: 10.1016/s1359-6446(03)02610-2

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  32 in total

1.  LINKER: a web server to generate peptide sequences with extended conformation.

Authors:  Fan Xue; Zhong Gu; Jin-an Feng
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association.

Authors:  Muppalla Sukumar; Brandon L Doyle; Jessica L Combs; Allen H Pekar
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

3.  Automated selection of stabilizing mutations in designed and natural proteins.

Authors:  Benjamin Borgo; James J Havranek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

4.  Role of conservative mutations in protein multi-property adaptation.

Authors:  David Rodriguez-Larrea; Raul Perez-Jimenez; Inmaculada Sanchez-Romero; Asuncion Delgado-Delgado; Julio M Fernandez; Jose M Sanchez-Ruiz
Journal:  Biochem J       Date:  2010-07-15       Impact factor: 3.857

5.  Protein thermostability calculations using alchemical free energy simulations.

Authors:  Daniel Seeliger; Bert L de Groot
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

6.  beta-Peptides as inhibitors of protein-protein interactions.

Authors:  Joshua A Kritzer; Olen M Stephens; Danielle A Guarracino; Samuel K Reznik; Alanna Schepartz
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

Review 7.  Strategic challenges in neurotherapeutic pharmaceutical development.

Authors:  Christopher C Gallen
Journal:  NeuroRx       Date:  2004-01

8.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

9.  Structure-based protocol for identifying mutations that enhance protein-protein binding affinities.

Authors:  Deanne W Sammond; Ziad M Eletr; Carrie Purbeck; Randall J Kimple; David P Siderovski; Brian Kuhlman
Journal:  J Mol Biol       Date:  2007-06-08       Impact factor: 5.469

Review 10.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.